- Report
- September 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- August 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- February 2025
- 184 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2024
- 200 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- June 2024
- 183 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- July 2024
- 139 Pages
United States
From €2862EUR$2,999USD£2,398GBP
- Report
- August 2021
- 50 Pages
United States
From €2291EUR$2,400USD£1,919GBP
- Report
- April 2021
China
From €2481EUR$2,600USD£2,079GBP
- Report
- October 2022
- 177 Pages
From €3293EUR$3,450USD£2,759GBP
- Report
- October 2022
- 174 Pages
North America
From €3293EUR$3,450USD£2,759GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3293EUR$3,450USD£2,759GBP
- Report
- October 2022
- 202 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- July 2022
- 255 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- January 2022
- 90 Pages
Global
From €1909EUR$2,000USD£1,599GBP

Insulin Glargine is a long-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose more efficiently. Insulin Glargine is a recombinant human insulin analog that is modified to reduce its solubility and prolong its action. It is available in both prefilled pens and vials.
Insulin Glargine is a key drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat diabetes, a chronic condition that affects millions of people worldwide. It is an important part of diabetes management, helping to control blood sugar levels and reduce the risk of complications.
Companies in the Insulin Glargine market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and Boehringer Ingelheim. Show Less Read more